CXCR2 and hepatocellular carcinoma: Blocking these axes with CCR2 and CXCR2 antagonists in the context of TACE reduces neutrophil and macrophage infiltration and hepatic progenitor cell activation, thus overcoming the TACE resistance of HCC.